CClinicalTrials.gg
CompletedNCT07856576Public healthUpdated Oct 2, 2026

Effect of a Social-Support-Based Educational Intervention on COVID-19-Related Anxiety and Perceived Social Support in Pregnant Women: A Randomized Pretest-Posttest Controlled Trial

An interventional study of Spouse-Inclusive Social Support Educational Intervention in Pregnancy, Anxiety and COVID-19, sponsored by Atefeh Dehnoalian. Completed at 1 site in Iran. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Atefeh Dehnoalian · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Dec 2021, registered Sep 2026).
Updated Oct 2, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Sex
Female
01

Study summary

The goal of this randomized controlled trial is to learn if a spouse-inclusive, social-support-based educational intervention can reduce COVID-19-related anxiety and improve perceived social support in pregnant women during public health emergencies. The main questions it aims to answer are:

  • Does the intervention reduce COVID-19-related anxiety in pregnant women compared to routine care?
  • Does the intervention improve perceived social support across its five dimensions (emotional, informational, tangible, affection, and positive social interaction)?

Researchers will compare a group of pregnant women and their spouses who receive the seven-session educational program to a control group that receives only routine prenatal care, to see if the intervention reduces anxiety and enhances social support.

Participants will:

  • Attend seven weekly 60-minute face-to-face sessions together with their spouses, which include group discussions, lectures, and Q\&A
  • Receive supplementary virtual messages (motivational and educational content) between sessions
  • Complete questionnaires measuring COVID-19 anxiety and perceived social support at three time points: before the intervention, immediately after, and one month later
02

Conditions studied

  • Pregnancy
  • Anxiety
  • COVID-19
  • Social Support

Keywords

  • Prenatal anxiety
  • Pregnancy
  • Social support
  • Spouse-inclusive intervention
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 110 is above the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

This is the only study on the registry with Atefeh Dehnoalian as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility Criteria

Inclusion criteria

Inclusion Criteria:

Gestational age of up to 34 weeks

Must be literate

Possess a registered pregnancy record at the health center

Own a smartphone

No documented history of physical or mental health disorders for either the pregnant woman or her spouse

Not involved in concurrent COVID-19 anxiety reduction programs

Exclusion criteria

Exclusion Criteria:

Experience of miscarriage or preterm birth during the study timeframe

Withdrawal of consent

Researcher-identified comprehension or learning difficulties

Missing more than two intervention sessions

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • No intervention
    Control Group

    Pregnant women who received standard routine prenatal care only, without any supplementary training regarding social support or COVID-19 anxiety reduction.

  • Experimental
    Intervention Group

    Pregnant women and their spouses who received the seven-session, spouse-inclusive, social-support-based educational intervention in addition to routine prenatal care. The intervention consisted of seven weekly 60-minute face-to-face sessions (limited to 11 couples per session) combining interactive discussions, formal lectures, and question-and-answer segments, reinforced by supplementary virtual messages containing motivational and educational content. Sessions covered an overview of the topic, participant introduction, program guidelines, session structure, and explanation of techniques. Outcomes were assessed at baseline, immediately post-intervention, and at a one-month follow-up.

    Behavioral: Spouse-Inclusive Social Support Educational Intervention

Interventions

  • BehavioralSpouse-Inclusive Social Support Educational Intervention

    A structured, seven-session educational program attended by both pregnant women and their spouses. Sessions were conducted face-to-face on a weekly basis, lasting 60 minutes each, and were facilitated by the lead researcher. Each session was limited to 11 couples to optimize group dynamics and interaction. The pedagogical approach integrated interactive discussions, formal lectures, and question-and-answer segments, which were further reinforced by supplementary virtual messages containing motivational and educational content.

06

What researchers measure

Primary outcomes

  1. COVID-19 Anxiety

    COVID-19-related anxiety measured by the Corona Disease Anxiety Scale (CDAS), an 18-item questionnaire assessing the psychological (items 1-9) and physical (items 10-18) symptoms of COVID-19-related anxiety. Responses are scored on a 4-point Likert scale ranging from 0 (never) to 3 (always), yielding a total score between 0 and 54, where higher scores indicate elevated anxiety levels. Reported Cronbach's alpha: 0.91.

    Time frame: Baseline, immediately post-intervention (after seven weekly sessions), and one-month follow-up.

  2. COVID-19 Anxiety

    COVID-19-related anxiety measured by the Corona Disease Anxiety Scale (CDAS), an 18-item questionnaire assessing psychological (items 1-9) and physical (items 10-18) symptoms. Responses are scored on a 4-point Likert scale ranging from 0 (never) to 3 (always), yielding a total score between 0 and 54, with higher scores indicating elevated anxiety. Reported Cronbach's alpha: 0.91.

    Time frame: Baseline, immediately post-intervention (after seven weekly sessions), and one-month follow-up.

07

Study locations

1 site
  • Mahdi Moshki
    Gonābād, Razavi Khorasan Province 05142632476, Iran
08

References and documents

Study documents

  • Study protocol · Jan 15, 2022
  • Statistical analysis plan · Jan 15, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Supporting information: Study protocol, Csr

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856576
Lead sponsor
Atefeh Dehnoalian
Responsible party
Atefeh Dehnoalian (Corresponding Author; Department of Nursing, Neyshabur University of Medical Sciences, Gonabad University of Medical Sciences) — Sponsor-investigator
First posted
Oct 2, 2026
Start date
Dec 10, 2021
Primary completion
Dec 10, 2024
Completion
Nov 15, 2025
Last update
Oct 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion